https://www.thebodypro.com/collection/hepatitis-c

Featured

FDA Approves Vosevi for Hepatitis C Img
Hepatitis C

FDA Approves Vosevi for Hepatitis C

"Vosevi provides a treatment option for some patients who were not successfully treated with other HCV drugs in the past."

Risk of HCV Reinfection Greatest in High-Risk MSM and Individuals Who Inject Drugs Img
Hepatitis C

Risk of HCV Reinfection Greatest in High-Risk MSM and Individuals Who Inject Drugs

Individuals who inject cocaine and methamphetamine and men who have sex with men (MSM) with high sexual risk had the greatest chance of hepatitis C (HCV) reinfection after sustained virologic response.

What Will It Take to Eliminate HCV in the U.S.? The WHO _Global Hepatitis Report_ Puts It Into the Global Context Img
Hepatitis C

What Will It Take to Eliminate HCV in the U.S.? The WHO Global Hepatitis Report Puts It Into the Global Context

According to the WHO's first-ever Global Hepatitis Report, approximately 1.75 million people were infected with hepatitis C in 2015, bringing the total number to 71 million. What can the US and other countries do to bring these numbers down?

Investigational Hepatitis C Drugs Show Promising Results Img
Hepatitis C

Investigational Hepatitis C Drugs Show Promising Results

Newer hepatitis C (HCV) drugs have shown very good sustained viral response rates and little risk of resistance-associated substitutions, David L. Wyles, M.D., reported in a webinar.

Addressing Hepatitis C Treatment Barriers Among HCV/HIV-Coinfected Patients Img
Hepatitis C

Addressing Hepatitis C Treatment Barriers Among HCV/HIV-Coinfected Patients

To help clinicians and patients navigate the challenges of HIV/HCV coinfection, AETC NCRC released an infographic that addresses the most common barriers preventing HIV-positive people from curing their HCV infection.

Cochrane Nonsense Review of HCV Treatment Misses Real Issues of Access to Care Img
Hepatitis C

Cochrane Nonsense Review of HCV Treatment Misses Real Issues of Access to Care

A Cochrane review of new hepatitis C drugs has discredited what can be a useful process for combining results from multiple studies, and irresponsible reporting of the review risks limiting access to effective treatment.

New Hepatitis C Infections Nearly Tripled Over Five Years Img
Hepatitis C

New Hepatitis C Infections Nearly Tripled Over Five Years

Over just five years, the number of new hepatitis C virus infections reported to the U.S. CDC has nearly tripled, reaching a 15-year high.

Where Harm Reduction Policies Went Up, Hepatitis C Incidence Went Down, Study Finds Img
Hepatitis C

Where Harm Reduction Policies Went Up, Hepatitis C Incidence Went Down, Study Finds

The first study of hepatitis C incidence and injecting behavior across cities and over 25 years showed the differences in incidence reflect differences in policies to reduce the harm of injecting drug use.

Shame Canada: Canadian Task Force Ignores Expert Advice in New Hepatitis C Screening Guidelines Img
Hepatitis C

Shame Canada: Canadian Task Force Ignores Expert Advice in New Hepatitis C Screening Guidelines

"The new screening guidelines ignore expert advice regarding who should be tested for hep C, setting a dangerous public health policy where dollars come first and the health of Canadians comes last."

Getting in Sync on HIV, Hepatitis C and LGBT Health Img
Hepatitis C

Getting in Sync on HIV, Hepatitis C and LGBT Health

The 2017 Synchronicity Conference, a national conference that focuses on HIV and hepatitis C, also addressed LGBT health for the first time this year.